Background Non-invasive ventilation is part of the standard of care for treatment of respiratory failure in patients with amyotrophic lateral sclerosis (ALS). The NeuRx RA/4 Diaphragm Pacing System has received Humanitarian Device Exemption approval from the US Food and Drug Administration for treatment of respiratory failure in patients with ALS. We aimed to establish the safety and effi cacy of diaphragm pacing with this system in patients with respiratory muscle weakness due to ALS.
Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is a neurodegenerative disorder in which death occurs on average 3 years after symptom onset, in most cases because of respiratory failure. 1 The only disease-modifying treatment is riluzole, a glutamaterelease modulator, which improves survival by an average of 3 months. 2, 3 Non-invasive ventilation is part of the standard of care for treatment of respiratory failure in patients with ALS, extending life by an average of 7 months. 4 However, non-invasive ventilation is not without problems, and claustrophobia, problems in the interface between device and patient, a physical barrier to communication, asynchrony between non-invasive ventilation and patients' natural breathing, a fairly poor uptake in patients with bulbar dysfunction, and concerns about increasing aspiration of secretions lead to adherence rates of roughly 72%. 5, 6 Therefore, an alternative or com plementary means of maintaining or supporting respiratory function is highly appealing.
Diaphragm pacing or, more accurately, phrenic nerve stimulation leading to contraction of the diaphragm, has historically largely been used in patients with spinal cord injury. Challenges with this approach have been the signifi cant risk of iatrogenic phrenic nerve injury and, until recently, the need to undertake a thoracotomy. 7 The NeuRx RA/4 Diaphragm Pacing System (Synapse Biomedical, Oberlin, OH, USA) has an advantage compared with the earlier approach in that the phrenic nerves are stimulated near the motor endpoints within the diaphragm muscle. 8 Therefore, a minimally invasive laparoscopic abdominal procedure can be used to insert the electrodes into the undersurface of the diaphragm.
Case series of the spinal cord injury and ALS populations have emphasised the apparent simplicity and operative safety of the NeuRx RA/4 Diaphragm Pacing System. 9, 10 Data from an uncontrolled multicentre cohort study led to Humanitarian Device Exemption approval of the Diaphragm Pacing System from the US Food and Drug Administration (FDA). 11 Since this approval on humanitarian grounds, insertion of the NeuRx RA/4 Diaphragm Pacing System as a treatment for respiratory failure in patients with ALS has become frequent practice worldwide. Although the evidence to date suggests that insertion of the NeuRx RA/4 Diaphragm Pacing System is a fairly straightforward procedure, and despite the encouraging provisional data for the benefi ts of diaphragm pacing, we and others 12 recognised the need to establish, by means of a randomised controlled trial, the long-term safety amd effi cacy of diaphragm pacing with the NeuRx RA/4 Diaphragm Pacing System when used in addition to non-invasive ventilation, compared with the standard care of non-invasive ventilation alone. 12 
Methods

Study design and participants
We did this multicentre, open-label, randomised controlled trial at seven specialist ALS and respiratory centres in the UK. The full protocol is described elsewhere. 13 Participants aged 18 years or older were eligible for inclusion if they had laboratory supported probable, clinically probable, or clinically defi nite ALS, according to the World Federation of Neurology revised El Escorial criteria; 14 were stabilised on riluzole treatment for at least 30 days; had respiratory insuffi ciency as determined by one or more of forced vital capacity (FVC) less than 75% predicted, supine vital capacity less than 75% of sitting or standing vital capacity, sniff nasal inspiratory pressure less than 65 cm H 2 O (men) or 55 cm H 2 O (women) in the presence of symptoms, sniff nasal inspiratory pressure less than 40 cm H 2 O, partial carbon dioxide pressure (PaCO 2 ) of more than 6 kPa (daytime) or 6·5 kPa (overnight), or signifi cant overnight O 2 desaturation (>5% of night with oxygen saturation <90% during overnight oximetry); and had clinically acceptable bilateral phrenic nerve function, defi ned either by the absence of paradoxical abdominal wall movement during a supine sniff manoeuvre (sharp inhalation through the nose) and less than a 10% decline of FVC when moving from sitting to supine position, or by ultrasound evidence of at least 1 cm of downward diaphragm movement independent of thoracic or abdominal wall movement during a sniff manoeuvre.
Exclusion criteria were previous use of non-invasive ventilation; a pre-existing implanted electrical device; underlying cardiac disease, pulmonary disease, or other disorders that would aff ect pulmonary tests independently of ALS, or increase the risk of general anaesthesia or adversely aff ect survival over the course of the study; current pregnancy or breastfeeding; signifi cant
Research in context
Evidence before this study We searched PubMed for reports published before April 1, 2015, with the terms "amyotrophic lateral sclerosis", "motor neuron disease", "ALS", "MND", and "diaphragm pacing". We included all prospective studies of diaphragm pacing in patients with amyotrophic lateral sclerosis (ALS). We did not identify any randomised controlled studies. We identifi ed one cohort study that has been partially reported in various publications, including in a summary of safety and probable benefi t (SSPB) published after Humanitarian Device Exemption approval for diaphragm pacing from the US Food and Drug Administration. In the SSPB, median overall survival for implanted patients was 56 months (4·7 years) from disease onset and 19 months (1·6 years) from implantation. A subgroup of patients were matched with historical controls and survival from diagnosis in the historical non-invasiveventilation control group (n=43) was 21·4 months compared with 37·5 months for non-invasive ventilation plus pacing (p<0·001).
Added value of this study
This is the fi rst randomised controlled trial of non-invasive ventilation alone versus non-invasive ventilation plus pacing. Patients receiving diaphragm pacing had decreased survival, unlike those in the previous cohort study of a selected ALS population, which showed a benefi t of diaphragm pacing.
Implications of all the available evidence
Our fi ndings suggest that diaphragm pacing should not be used as a treatment for patients with ALS at the point of respiratory failure. The disparity between our results and those of the previous uncontrolled cohort study demonstrates the importance of undertaking randomised controlled trials to identify benefi ts and exclude harm of interventions, whether they are drugs or medical devices.
decision-making incapacity preventing informed consent; obesity aff ecting surgical access to the diaphragm, or signifi cant scoliosis or chest-wall deformity; involvement in any respiratory trial that could aff ect the safety or outcome measures of this study within 3 months of the planned implantation of the device or during the year of follow-up; pre-existing diaphragm abnormality, such as a hiatus hernia or paraoesophageal hernia, leading to ascent of abdominal contents into the thoracic cavity; and an FVC of less than 50% predicted or a sniff nasal inspiratory pressure of less than 30 cm H 2 O in patients unable to undergo FVC (eg, patients with bulbar muscular atrophy) because of potential anaesthetic risk. These criteria are consistent with the indications for use outlined in the FDA summary of safety and probable benefi t (SSPB) report for the NeuRx RA/4 diaphragm pacing system.
11
Patients provided written informed consent before screening or, for individuals unable to write, verbal consent was given and a witness signed to acknowledge the consent of the participant. The East of England Central Cambridge Research Ethics Committee provided ethics approval for the study (reference 11/EE/0226).
Randomisation and masking
We randomly assigned patients (1:1), via a central webbased randomisation system, to receive either noninvasive ventilation plus diaphragm pacing with the NeuRx RA/4 Diaphragm Pacing system or non-invasive ventilation alone (control group). The fi rst ten participants were allocated with simple randomisation and thereafter patients were allocated by non-deterministic minimisation (with an allocation probability of 0·8), balancing for age, sex, FVC, and bulbar function. Patients, carers, and outcome assessors were not masked to treatment allocation.
Procedures
Scheduled follow-up visits were at months 2, 3, 6, 9, and 12 after randomisation. Sites were allowed to initiate non-invasive ventilation in both groups any time after commencing screening as per their standard practice. A minimum target of 4 h of overnight use of non-invasive ventilation was set for patients, who were encouraged to use non-invasive ventilation for as long as possible overnight and, if clinically required, during the daytime.
For patients allocated to diaphragm pacing, surgery was scheduled for as soon as was practicable after randomisation. Before surgery, a preoperative assessment was done to ensure the respiratory criteria for each patient remained within the safe range for anaesthesia (FVC ≥45%, sniff nasal inspiratory pressure ≥30 cm H 2 O) and to ensure that they were otherwise safe to undergo the procedure. The procedure for insertion of the NeuRx RA/4 Diaphragm Pacing System was done as previously described and is detailed in the appendix. 9 ,10,13
The initial target for pacing sessions was fi ve times per day, with each session lasting at least 30 min. Patients were advised to build up to this target over the fi rst month. In the second month, patients were asked to gradually lengthen the pacing sessions. When using the pacing system for 6-7 h a day, patients were advised to switch from pacing during the day to pacing overnight whilst asleep. At this stage patients were allowed to use the pacing device additionally during the day if they experienced benefi t. Adherence to target use of diaphragm pacing and non-invasive ventilation was recorded by a study nurse at each follow-up in a patient diary and also at each follow-up visit, at which patients were asked how much they had paced or used noninvasive ventilation on a typical day that they identifi ed within the previous week; use was categorised post hoc as high use (≥4·0 h per day), low use (1·0-3·9 h), or no use (<1 h). Usage data for non-invasive ventilation were downloaded from non-invasive ventilation machines when available. Means were calculated from the machine data and diary data available since the previous study visit. 759 15 ) and health-care resource use; and tolerability and adverse events. Categorisation of adverse events was done with no knowledge of treatment allocation. A post-hoc analysis of tracheostomy-free survival (ie, the time from randomisation to the insertion of tracheostomy or death) was done to aid comparability with other studies of ALS.
Statistical analysis
The trial was powered to detect a 12 month survival improvement from 45% to 70%, corresponding to a hazard ratio (HR) of 0·45. With a schedule of 18 months' recruitment, 12 months' follow-up, and control group survival of 20% at 24 months and 10% at 30 months, 108 patients (54 per group) were needed to record the 64 events required by the log-rank test, with 85% power, a two-sided type I error of 5%, and 10% additional dropout. 16 We analysed overall survival and tracheostomy-free survival with Cox regression, with minimisation factors as covariates. We did a sensitivity analysis with the log-rank test stratifi ed by centre. We analysed quality of life with a longitudinal model (generalised least squares) with baseline quality of life and minimisation factors as covariates. Missing data were imputed for survivors, fi rst by interpolation if possible, and otherwise by multiple imputation. For further analysis of EQ-5D-3L, we used an imputed score of zero for timepoints following participant death. Analyses were by intention to treat, with preplanned secondary analyses of overall survival based on protocol adherence and usage of non-invasive ventilation. Additional unplanned analyses of survival in relation to non-invasive ventilation and pacing usage were added thereafter. There was no planned interim analysis. The trial was overseen by an independent Trial Steering Committee and an independent Data Monitoring and Ethics Committee (DMEC). The DMEC monitored the results provided by the trial statistician with reference to safety. During this monitoring, a potential safety signal was identifi ed and an unplanned interim survival analysis was done. Additional post-hoc (exploratory) analyses were subsequently added to investigate whether this signal could be explained by other factors, in particular, by use of non-invasive ventilation. We did analyses with Stata (version 12.1) and primary analyses were verifi ed with SAS (version 9.4). 17 This study is registered, ISRCTN number 53817913.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and the corresponding author had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. Between Dec 5, 2011, and Dec 18, 2013, we randomly assigned 74 participants to receive either non-invasive ventilation alone (n=37) or non-invasive ventilation plus diaphragm pacing (n=37; fi gure 1). On Dec 18, 2013, the DMEC recommended that recruitment be suspended on the basis of a concerning (table 3) . Non-invasive-ventilation usage was similar between groups (table 3) . The appendix shows the association between adherence to non-invasive ven tilation and overall survival. Although the diff erence between the non-invasive ventilation plus pacing and the non-invasive ventilation alone groups was greatest in the non-users subgroup, pacing was not more eff ective in any of the three subgroups of high, low, or no use (table 2) . The association between overall survival and average noninvasive ventilation use was non-signifi cant, with the HR for the linear association 0·97 per additional hour use (95% CI 0·92-1·04; p=0·52). No association was evident with pacing use (HR 1·00 per additional hour use, 95% CI 0·92-1·09; p=0·92). Five (14%) participants in the pacing group did not undergo surgery because of a rapid decline in respiratory function to lower than the safety threshold for surgery (n=1), patient choice (n=2), and the DMEC intervention (n=2); a sixth patient had technical problems with the device and did not begin regular pacing (fi gure 1, table 3). Exclusion of these patients from the analysis did not change the fi ndings, with the adjusted HR increasing when non-users were excluded (HR 2·71, 95% CI 1·39-5·27). All participants who underwent surgery had a successful implantation and a diaphragm that could be stimulated. When used, median daily usage was 4·6 h (IQR 3·0-8·4 h), with no association between daily use and survival (table 3) . Most participants receiving diaphragm pacing were able to achieve the target pacing settings within 15 days of surgery and continued to titrate successfully over the course of the study as per the study protocol (table 3, appendix). Pacing was well tolerated, with only two (5%) patients choosing to discontinue pacing at months 6 and 12 after starting regular use.
Results
The patient health utility (EQ-5D-3L) score was slightly lower with diaphragm pacing plus non-invasive ven tilation than with non-invasive pacing alone, and the diff erences were signifi cant when a score of zero was imputed to EQ-5D-3L after death (table 2, appendix). Other patient qualityof-life questionnaires were similar between the two groups, as were all carer quality-of-life measures ( A separate cost-utility analysis was planned; however, in view of the low effi cacy of diaphragmatic pacing, this analysis did not proceed. We have included the quality-oflife component of the planned cost-utility analysis from the EQ-5D-3L to complement the SF-36 and SAQLI data. The appendix shows data for health-care resource use. Notably, the number of patients using aids (cough-assist devices, breath stacking, and suction machines) was similar between groups, but those who did use a mechanical cough-assist device or a suction machine tended to do so more in the non-invasive ventilation alone group, and those who used breath stacking tended to do so more in the pacing group (appendix).
Discussion
Our fi ndings show that addition of diaphragm pacing to the standard care of non-invasive ventilation was associated with decreased survival in patients with ALS. This result is in contradiction with the FDA SSPB, which reported a survival advantage for diaphragm pacing of 16·1 months from symptom onset and 9 months from the point of initiation of non-invasive ventilation, compared with non-invasive ventilation alone in a historical cohort. 11, 18 Median survival from symptom onset in our study was 45 months in the non-invasive ventilation group and 28 months in the pacing group, compared with 56 months in the SSPB pacing study.
The complete dataset from the uncontrolled multi centre cohort study that led to FDA approval of the NeuRx RA/4 Diaphragm Pacing System on humanitarian grounds has to date not been published, although descriptions of safety and effi cacy are available for the fi rst 16 patients enrolled in the pilot phase of that study. 19 This partial reporting makes full understanding of the diff erences in the reported outcomes challenging. Some results are available within the FDA SSPB, in which 144 patients were reported to have been enrolled to the pilot and pivotal phases of that cohort study. The primary inclusion criteria were evidence of residual bilateral phrenic nerve function and an FVC of less than 85% at screening and more than 45% at implantation of the pacing system. 11 106 (74%) of the 144 participants were implanted with the Pacing System. Details of the 38 (26%) patients who did not undergo implantation are not reported.
To establish whether the NeuRx RA/4 Diaphragm Pacing System met the Humanitarian Device Exemption criteria in ALS, analyses for the FDA SSPB were done in a subgroup of the 106 patients who were implanted. For survival analyses, this subgroup consisted of 84 patients For this comparison, the investigators selected patients (N=43) from the Humanitarian Use Designation group with an FVC between 45% and 65%. Survival from diagnosis in the historical non-invasive-ventilation dataset (N=43) was 21·4 months, compared with 37·5 months for the pacing and non-invasive ventilation group (p<0·001). Survival from initiation of non-invasive ventilation was 11·9 months for the historical group and 20·9 months for the pacing and non-invasive ventilation group.
The patient population in the present study is characteristic of the ALS population in terms of age, sex, site of onset, and proportion with a clear family history; 20 the population from which the subgroup data used in the FDA SSPB were obtained might be less generalisable to the wider ALS population. 11 The cohort study contained a lead-in phase of 3 months during which time patients were monitored, and not all went on to have implantation. Because of the progressive nature of ALS, some patients might have become ineligible, with their FVC decreasing to less than the study implantation safety threshold of 45% during the 3 months. This possibility might have enriched the implanted population with individuals who have a more slowly progressive disease course. However, whether such enrichment happened is not clear, and other criteria might have been used. Of the 106 patients who were implanted, data for only 84 patients contribute to the SSPB report, with two patients having been lost to follow-up and 20 patients not meeting the Humanitarian Use Device criteria. This cohort is therefore a selected group and might not be generalisable to the wider ALS population. By contrast, we used an intention-to-treat approach in which all consenting participants were analysed, including those who subsequently declined rapidly in either group.
The apparent harm recorded in the pacing group was not obviously due to immediate surgical complications, with no deaths within 30 days of procedure and only one within the fi rst 3 postoperative months. However, a retrospective review of patients with ALS undergoing surgery for any cause showed an apparent acceleration of ALS disease progression post-surgery, suggesting a potential disease-modifying eff ect, albeit one that is not fully understood. 21 The survival diff erences in our study might partly be explained by such a process, which supports previous wider concerns regarding the undertaking of operative procedures in individuals with ALS. A further possibility is that the harm is due to a direct eff ect of the pacing, perhaps because stimulation of already damaged motor neurons is harmful. The physiological eff ects of pacing have not been studied in human beings.
Findings from studies of canine and rodent models show that neuromuscular damage can be induced dependent on the parameters of pacing and that the eff ects recorded diff er between healthy and disease models. 7, 22 A simpler explanation could be that pacing causes excessive muscle fatigue, or that asynchrony between pacing-induced diaphragm contraction and breaths triggered by patients or non-invasive ventilation is an issue. We cannot exclude the possibility that a small subgroup of patients might benefi t from diaphragm pacing. One particular group who might have most to gain from pacing would be low users of non-invasive ventilation-eg, patients with signifi cant bulbar dysfunction. However, we noted the greatest diff erence in survival in low users of noninvasive ventilation; therefore, diaphragm pacing alone cannot be recom mended as an alternative to non-invasive ventilation. Because of the small sample size, we are unable to make meaningful attempts to investigate possible subgroup eff ects further.
Our study has some limitations. Patients allocated to diaphragm pacing underwent surgical intervention and could not be masked to the intervention. The study assessors were also unmasked to the intervention. The trial statistician (MJB) was unmasked and gave survival data to the DMEC but withheld accumulating data from the study team. Because the primary outcome measure was objective (overall survival), the risk of bias is small, but some risk is unavoidable in the subjective patient-reported secondary outcome measures. We con sidered inserting the pacing devices in patients receiving non-invasive ventilation alone, but not connecting them (sham pacing), to reduce the risk of bias and be able to off er pacing to control patients at the end of the 12 month follow-up period, but concluded that this approach would be less rational in the event of an outcome showing no benefi t of pacing. The eff ect of pacing on the ongoing use of noninvasive ventilation was a concern, and we asked whether patients stopped using the non-invasive ventilation system, which has established survival benefi t, in favour of the pacing system. However, daily periods of non-invasive ventilation use were similar across both groups. Minor imbalances exist between the treatment groups in our study, with patients in the pacing group being slightly older than those in the non-invasive ventilation alone group. We have adjusted the hazard ratios for the covariate of age and propose that such a small age diff erence is unlikely to have had a large eff ect on ALS survival. Similar numbers of patients across each group were reported to receive additional respiratory interventions. However, we noted diff erences across the treatment groups in the frequency of use of cough-assist devices, suction machines, and breath-stacking techniques among individuals given devices. The eff ects of these diff erences are unknown, but again, are unlikely to explain the poor survival in the noninvasive ventilation plus pacing group.
In conclusion, diaphragmatic pacing should not be a routine treatment for patients with ALS in respiratory failure. A subgroup of patients might experience a benefi t; however, this possibility should not be assumed. Our fi ndings suggest that insertion of the NeuRx RA/4 Diaphragm Pacing System at the point an individual with ALS develops respiratory insuffi ciency is harmful. Whether there is a point earlier in the disease trajectory when implantation and pacing might be of benefi t is unknown and is currently being investigated (ClinicalTrials.gov, number NCT01583088). A poor prognosis and the absence of curative treatment understandably encourage a nothing to lose approach in patients and some clinicians alike, with an attendant lowering of the standards of evidence needed to adopt a new intervention. 23 Our fi ndings show the potential for harm that can arise from adopting this approach.
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